Microbot Medical
MBOT
36 hedge funds and large institutions have $2.57M invested in Microbot Medical in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 5 closing their positions.
81% more capital invested
Capital invested by funds: $1.41M → $2.57M (+$1.15M)
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
63% more call options, than puts
Call options by funds: $109K | Put options by funds: $67K
13% more funds holding
Funds holding: 32 → 36 (+4)
4.68% more ownership
Funds ownership: 8.57% → 13.26% (+4.7%)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$399K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$264K |
| 3 |
HF
HRT Financial
New York
|
+$77.2K |
| 4 |
Morgan Stanley
New York
|
+$34.7K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$71.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$44.6K |
| 3 |
Renaissance Technologies
New York
|
-$23.4K |
| 4 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$15K |
| 5 |
BAM
Byrne Asset Management
Kingston,
New Jersey
|
-$5.06K |
MBOT Hedge Fund Activity: Q4 2023 in Review
36 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q4 2023, worth a combined $2.57M — up 81% from $1.41M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new MBOT positions and 5 closed out — a net gain of 4 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $399K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $71.4K sold.
- 36 institutional investors held Microbot Medical (MBOT) as of Q4 2023, up from 32 in Q3 2023.
- Funds reported $2.57M of Microbot Medical stock for Q4 2023, up 81% quarter-over-quarter.
- 9 funds opened new Microbot Medical positions in Q4 2023 and 5 closed out, a net change of +4 holders.
- The largest Microbot Medical buyer in Q4 2023 was Armistice Capital, an estimated $399K added.
- The largest Microbot Medical seller in Q4 2023 was Bank of New York Mellon, an estimated $71.4K sold.
Based on aggregated 13F filings for Q4 2023.